The companies have established a memorandum of understanding (MOU) to collaborate on Innocell, a therapeutic vaccine for solid tumors.
Terumo will provide its Mirasol Pathogen Reduction Technology (PRT) for use in the manufacturing process. The initial agreement authorizes PhotonPharma to reference the Device Master File (DMF) on record with the FDA for the Mirasol system, which will then support the regulatory submission for the Innocell therapeutic vaccine technology. Terumo will also supply Mirasol illuminators and single-use sets for the immunotherapy preparation process used in the clinical trial.
PhotonPharma is currently preparing for an IND submission related to a phase I clinical trial in triple-negative breast cancer – and according to a press release, the MOU is just the beginning of a longer-term collaboration to advance Innocell, and will focus on the development, regulatory approval, and commercialization of the vaccine.
Terumo’s CEO and president, Antoinette Gawin, commented in the press release: “for Terumo, strategic collaborations increase the potential speed to market and decrease development costs of therapies. This will enable patients to benefit from therapies earlier. Contributing toward the development and commercialization of Innocell enables Terumo to contribute toward the next potential major medical breakthrough."